Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Nearly 43% of Pharmacies Now Receive Class 3 Fee for Generic Drug Dispensing Systems: Survey
April 17, 2013
- Astellas Appoints Dr Xue as Head of GPV
April 17, 2013
- FDA Accepts Otsuka Tolvaptan NDA for Priority Review
April 17, 2013
- Chugai Voluntarily Recalls Digosin Tablets
April 16, 2013
- Toho Holdings Establishes New Company for Distribution Management of Specialty Drugs
April 16, 2013
- MAA for Lurasidone Accepted in Australia: DSP
April 16, 2013
- Hisamitsu Sales Up 3.6% Helped by Mohrus Tape Sales Recovery
April 15, 2013
- Over Half of Domestic, Foreign-Affiliated Drug Makers Hired Fewer New Graduates This Year: Survey
April 15, 2013
- 11 Drug Makers to Increase, 11 to Decrease Hiring Next Year; Mid-Sized Companies Most Optimistic on Hiring
April 15, 2013
- Astellas to Conduct Interim Analysis for PIII Study of Enzalutamide in mCRPC within 2013
April 15, 2013
- Santen to Disclose Payments to Patient Groups in FY2014
April 15, 2013
- Pfizer Japan Launches Intestinal Amebiasis Treatment on April 12
April 12, 2013
- Daiichi Sankyo Sets Up Office of New Company Specialized in DMD Treatments
April 12, 2013
- Daiichi Sankyo Sets Up Office of New Company Specialized in DMD Treatments
April 12, 2013
- Eisai Announces Organizational Reforms; “We Won’t Allow Generics to Overwhelm AD Market”: President Naito
April 12, 2013
- Sanofi K.K. Sales Grew 5.7% in 2012, Plavix Enjoys Sales Success
April 11, 2013
- Ethical Drug Sales Fall 1.7% in February as Flu Season Slows Down: Crecon Report
April 11, 2013
- Teva Pharma Voluntarily Recalls Enalapril Maleate Tablets
April 11, 2013
- Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
April 11, 2013
- Fujimoto’s Safety Procedures TERMS Takes Effect April 1, Celgene’s RevMate June 1
April 10, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…